Jason Robart
About Jason Robart
Independent director at SiriusPoint Ltd. (SPNT) since March 2022; age 59. Robart is co‑founder and Managing Partner of Seae Ventures (early‑stage VC). Prior roles include Chief Strategy Officer at Blue Cross Blue Shield of Massachusetts and President/CEO of Zaffre Investments (BCBSMA subsidiary). He holds a BA in Political Science from Middlebury College. Board assigns him committee leadership and oversight roles based on expertise in business strategy, healthcare, venture investing, digital strategy, and human capital management .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Seae Ventures | Co‑founder & Managing Partner | 2019–present | Early‑stage healthcare/tech venture investing |
| Blue Cross Blue Shield of Massachusetts | Chief Strategy Officer | Not disclosed | Strategy leadership; President & CEO of Zaffre Investments (subsidiary) |
| Zaffre Investments (BCBSMA subsidiary) | President & CEO | Not disclosed | Corporate venture/innovation investing |
| Health Dialog | Executive Vice President | Not disclosed | Population health/analytics (EVP) |
| Mercer Human Resource Consulting | Principal | Not disclosed | Human capital/benefits consulting |
| Imagitas | Vice President | Not disclosed | Growth/operations (VP) |
| Ceridian Performance Partners Canada | President | Not disclosed | Business leadership |
External Roles
| Organization | Role | Type | Notes |
|---|---|---|---|
| Blue Cross Blue Shield, Vermont | Director (private board) | Private/non‑profit insurer | Current private board service |
| Hurdle (Seae portfolio) | Director | Private company | Seae portfolio board role |
| Kiyatec (Seae portfolio) | Director | Private company | Seae portfolio board role |
| MyMeds (Seae portfolio) | Director | Private company | Seae portfolio board role |
| ScriptSee (Seae portfolio) | Director | Private company | Seae portfolio board role |
No other public company directorships were disclosed for Mr. Robart in SPNT’s proxy .
Board Governance
| Item | Detail |
|---|---|
| Independence | Determined independent under NYSE and SEC rules (Feb 2025 review) |
| Years of service | Director since March 2022 (Class II; term expires 2027) |
| Committee assignments | Compensation (Chair); Audit (Member); Investment (Member) |
| Attendance | 100% attendance at Board and committee meetings in 2024 |
| Executive sessions | Board held independent director executive sessions at regularly scheduled meetings/calls (four in 2024) |
| Lead Independent Director | Not applicable; Board has independent Chair (Bronek Masojada) |
| Overboarding policy | Directors limited to ≤4 other public company boards; Audit members ≤2 other public company audit committees |
Fixed Compensation (Director)
| Component (2024) | Amount | Notes |
|---|---|---|
| Annual cash retainer | $137,500 | Independent director cash retainer |
| Committee chair fee | $20,000 | Compensation Committee Chair fee |
| Total cash (2024 actual) | $157,500 | Fees earned for 2024 |
| Equity grant (grant‑date FV) | $137,500 | Annual restricted share grant policy amount |
| Total 2024 compensation | $295,000 | Cash + equity grant FV |
Policy notes:
- Director equity grants typically made around AGM; number of shares based on FMV at grant; vest at next AGM (one‑year vest) .
- Non‑independent directors receive no director compensation .
Performance Compensation (Director Equity Detail)
| Grant date | Instrument | Shares/Units | Grant‑date fair value | Vesting |
|---|---|---|---|---|
| May 21, 2024 | Restricted Shares | Not individually itemized; unvested balance shown below | $137,500 | Vests May 31, 2025, subject to service |
| Unvested restricted shares (12/31/2024) | RS (unvested) | 22,216 | N/A | Scheduled to vest by next AGM cycle |
- Director awards are time‑based RS/RSUs; no performance‑conditioned PSUs or stock options were disclosed for non‑employee directors in 2024 .
Other Directorships & Interlocks
- Compensation Committee interlocks/insider participation: none in 2024; no members were company officers; no relationships requiring Item 404 disclosure for 2024 .
- Outside advisor: Mercer retained by Compensation Committee; independence assessed with no conflicts identified .
Expertise & Qualifications
- Board biography highlights experience in business strategy, healthcare, venture investing, digital strategy, and human capital management; cited as reasons for Board service .
- Board skills matrix indicates broad coverage across governance, financial literacy, risk management, and related domains for the full Board; Robart is included among directors with these competencies .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (common) | 83,944 shares (0.07% of class) as of March 14, 2025 |
| Unvested director restricted shares (12/31/2024) | 22,216 unvested restricted shares |
| Shares underlying awards vesting within 60 days (as of 3/14/2025) | None listed for Mr. Robart |
| Ownership guidelines | Directors must own ≥3× annual cash retainer within five years; all independent directors have achieved or are on track |
| Pledging/Hedging | Prohibited for directors and executives (no margin accounts/pledges; no hedging) |
Governance Assessment
- Strengths: Independent status, chair of Compensation Committee, 100% attendance, meaningful equity alignment through annual restricted shares, and robust ownership/anti‑hedging policies support alignment with shareholders .
- Process integrity: Compensation Committee free of interlocks; uses independent consultant (Mercer) with no conflicts; Board conducts annual evaluations and regular executive sessions without management .
- Potential conflicts: Robart leads a healthcare‑focused VC (Seae Ventures) and serves on several private boards; SPNT disclosed related party transactions with CM Bermuda and Third Point but none involving Mr. Robart .
- Shareholder signals: 2024 say‑on‑pay approval was ~82%, indicating broad investor support for compensation programs (context for overall governance climate) .
No red flags identified related to attendance, overboarding, pledging/hedging, or related‑party dealings for Mr. Robart based on the latest proxy. Continued monitoring of any Seae Ventures portfolio interactions with SPNT counterparties is prudent, though none were disclosed in 2024–2025 filings – .